YAN Wenying,TAO Xinyue,FENG Bing.Cost-effectiveness analysis of toripalimab combined with paclitaxel in the treatment of metastatic or recurrent triple-negative breast cancer[J].ZHONGGUO YAOFANG,2025,36(03):336-340.
YAN Wenying,TAO Xinyue,FENG Bing.Cost-effectiveness analysis of toripalimab combined with paclitaxel in the treatment of metastatic or recurrent triple-negative breast cancer[J].ZHONGGUO YAOFANG,2025,36(03):336-340. DOI: 10.6039/j.issn.1001-0408.2025.03.13.
Cost-effectiveness analysis of toripalimab combined with paclitaxel in the treatment of metastatic or recurrent triple-negative breast cancer
To evaluate the cost-effectiveness of toripalimab combined with paclitaxel (albumin binding type) in the treatment of metastatic or recurrent triple-negative breast cancer (TNBC).
METHODS
2
Based on the data of TORCHLIGHT clinical trial, a three-state partitioned survival model including progression-free survival, disease progression, and death was established. The simulation cycle was 21 days, the study duration was 10 years, and the discount rate was 5%. Using quality-adjusted life year (QALY) and cost as output indicators, a cost-effectiveness analysis method was adopted to calculate the incremental cost-effectiveness ratio (ICER) of toripalimab combined with paclitaxel (albumin binding type) versus placebo combined with paclitaxel (albumin binding type). Using three times the per capita gross domestic product (GDP) of China in 2023 as the willingness-to-pay(WTP) threshold(268 074 yuan/QALY), the cost-effectiveness of the above two regimens was evaluated, and the sensitivity analysis was conducted.
RESULTS
2
ICER of toripalimab combined with paclitaxel (albumin binding type) versus placebo combined with paclitaxel (albumin binding type) in the treatment of Chinese metastatic or recurrent TNBC patients was 176 347.17 yuan/QALY, which was lower than the WTP threshold set in this study, demonstrating the cost-effectiveness of this regimen. The results of the single-factor sensitivity analysis showed that the parameters such as the cost of toripalimab, discount rate, and utility value of the progression-free survival state had a great impact on the ICER. The results of the probabilistic sensitivity analysis indicated that the results of the basic analysis were robust.
CONCLUSIONS
2
When three times the per capita GDP of China in 2023 is used as the WTP threshold, compared with the regimen of placebo combined with paclitaxel (albumin binding type), toripalimab combined with paclitaxel (albumin binding type) is cost-effective in the treatment of metastatic or recurrent TNBC.
关键词
特瑞普利单抗三阴性乳腺癌成本-效果分析药物经济学分区生存模型
Keywords
triple-negative breast cancercost-effectiveness analysispharmacoeconomicspartitioned survival model
references
SUNG H,FERLAY J,SIEGEL R L,et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021,71(3):209-249.
SUN X M,GAO S G. Current situation and new progress of clinical treatment of triple negative breast cancer[J]. Pract J Cancer,2020,35(6):1037-1039.
ZHOU C C,WANG Z P,SUN Y P,et al. Sugemalimab versus placebo,in combination with platinum-based chemotherapy,as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302):interim and final analyses of a double-blind,randomised,phase 3 clinical trial[J]. Lancet Oncol,2022,23(2):220-233.
ZHANG D M,CHEN M Y,XU J,et al. Research progress on small molecule inhibitors of PD-1/PD-L1[J]. China Pharm,2024,33(12):1-6.
JIANG Z F,OUYANG Q C,SUN T,et al. Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer:a randomized phase 3 trial[J]. Nat Med,2024,30(1):249-256.
Guidelines Working Committee of Chinese Society of Clinical Oncology. Chinese Society of Clinical Oncology (CSCO) guidelines for the diagnosis and treatment of breast cancer 2023[M]. Beijing:People’s Health Press,2023:83-104.
LEVY-PIEDBOIS C,DURAND-ZALESKI I,JUHEL H,et al. Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer[J]. Ann Oncol,2000,11(2):157-161.
ZHANG Y,ZHANG C Y,WAN D G. Progress in intensive treatment of early triple-negative breast cancer after neoadjuvant and adjuvant therapy[J]. J China Jpn Friendsh Hosp,2023,37(1):31-34.
QI R. Pharmacoeconomic evaluation of pembrolizumab plus chemotherapy regimens for the first-line treatment of advanced triple-negative breast cancer[D]. Shijiazhuang:Hebei Medical University,2023.
HUANG X T. Cost-effectiveness analysis of atezolizumab combined with albumin-bound paclitaxel in the first-line treatment of advanced triple negative breast cancer[D]. Fuzhou:Fujian Medical University,2020.
FAN X. Pharmacoeconomic evaluation and application of sintilimab in the treatment of advanced or metastatic esophageal cancer based on zonal survival model[D]. Hefei:Anhui Medical University,2023.
ZHANG S,JIA C F,XU H,et al. Pharmacoeconomics evaluation of utidelone combined with capecitabine in the second-line treatment of metastatic breast cancer[J]. Chin J Mod Appl Pharm,2023,40(19):2732-2737.
WANG L,LIU L L,ZHANG Z,et al. Cost-effectiveness of sacituzumab govitecan versus single-agent chemotherapy for patients with metastatic triple-negative breast cancer in China[J]. Clin Breast Cancer,2024,24(7):e545-e553.
ZHU X C,WANG C P,ZHENG Y,et al. Pharmacoeconomic evaluation of liposomal amphotericin B in empiric treatment of invasive fungal infections[J]. Clin Med J,2023,21(11):12-19.
CHEN B W. Effect and safety of immune checkpoint inhibitors combined with chemotherapy in triple negative breast cancer: a meta-analysis[D]. Zhangjiakou:Hebei North University,2021.
SHAO J B,ZHAN C P,JIN C X,et al. Cost-effectiveness analysis of toripalimab for metastatic or recurrent triple-negative breast cancer[J]. Front Oncol,2024,13:1268584.